Hosted on MSN

First subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525

Vir Biotechnology has dosed the first subject in the non-randomised Phase I trial to assess VIR-5525, the investigational dual-masked T-cell engager (TCE) that targets epidermal growth factor receptor ...
BroadwayWorld

Vir Das Will Bring MIND FOOL to the UK For the First Time

On Friday, 15 December, as part of a major tour of iconic world venues, India’s biggest stand-up comedian will perform his hit show MIND FOOL at the Eventim Apollo. This is its UK premiere, with ...
Nasdaq

First Week of April 14th Options Trading For Vir Biotechnology

Investors in Vir Biotechnology Inc (Symbol: VIR) saw new options become available this week, for the April 14th expiration. One of the key inputs that goes into the price an option buyer is willing to ...
Investing

Vir Biotechnology doses first patient in VIR-5500 expansion trial

SAN FRANCISCO - Vir Biotechnology, Inc. (NASDAQ:VIR) announced Monday that it has dosed the first patient in an expansion cohort of its Phase 1 trial evaluating VIR-5500, a prostate-specific membrane ...